|1.||Costa, José Ricardo Sousa: 1 article (06/2011)|
|2.||de Figueiredo, Paulo Jeovane: 1 article (06/2011)|
|3.||Torriani, Marcos Antonio: 1 article (06/2011)|
|4.||D'Avila, Otávio Pereira: 1 article (06/2011)|
|5.||Hosni, Elaini Sickert: 1 article (06/2011)|
|6.||Kaneko, Yoshiyuki: 1 article (07/2007)|
|7.||Terada, Naoki: 1 article (07/2007)|
|8.||Nishimura, Kazuo: 1 article (07/2007)|
|9.||Okada, Yoshiyuki: 1 article (07/2007)|
|10.||Arakaki, Ryuichiro: 1 article (07/2007)|
06/01/2001 - "In this study, the efficacy of a sclerosing agent (monoethanolamine oleate) was evaluated for the treatment of pyogenic granuloma. "
06/01/2001 - "Pyogenic granuloma was treated by local injection of the monoethanolamine oleate solution in nine patients who were from 1 to 57 years of age (median 18 years). "
06/01/2001 - "Sclerotherapy with monoethanolamine oleate is effective in the treatment of pyogenic granuloma and offers an alternative to conventional methods in cases for which conservative treatment is preferable."
06/01/2011 - "The aim of the present study was to relate the use of 5% monoethanolamine oleate in sclerotherapy for vascular malformations and to suggest a protocol for its use. "
06/01/2011 - "A total of 53 patients with 66 vascular malformation lesions were treated with an intralesional injection of 5% monoethanolamine oleate at 0.1 mL/cm of lesion with at least a 15-day interval and as many as 4 applications. "
|4.||Obstructive Jaundice (Cholestatic Jaundice)
|5.||Acute Liver Failure (Fulminant Hepatic Failure)